| Valuation method | Value, CHF | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 161.56 | 18686 |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Evolva Holding SA (EVE.SW) is a Swiss biotechnology company specializing in the discovery, research, development, and commercialization of nature-based ingredients for the flavor and fragrance, health ingredients, and health protection sectors. Headquartered in Reinach, Switzerland, Evolva leverages synthetic biology to produce sustainable, high-value compounds such as Veri-te Resveratrol, L-Arabinose, Valencene, Nootkatone, and Vanillin. These ingredients are used in food, beverage, cosmetics, and pharmaceutical applications, offering natural alternatives to synthetic chemicals. With operations in Switzerland, the United States, and internationally, Evolva focuses on innovation in biotechnology to address growing consumer demand for natural and sustainable products. The company, founded in 2004, plays a key role in the intersection of biotechnology and green chemistry, positioning itself as a leader in sustainable ingredient solutions.
Evolva Holding SA presents a high-risk, high-reward investment opportunity in the biotechnology sector. The company operates in a niche market with strong growth potential due to increasing demand for natural and sustainable ingredients. However, its financials reveal challenges, including negative operating cash flow (-CHF 2.44 million) and no reported revenue, indicating reliance on funding for R&D and commercialization efforts. The company's net income of CHF 1.04 million and diluted EPS of CHF 0.14 suggest some profitability, but its negative beta (-0.106) indicates low correlation with the broader market, which may appeal to investors seeking diversification. The lack of debt and a cash position of CHF 6.75 million provide some financial stability, but the absence of dividends and uncertain revenue streams may deter conservative investors. Evolva's success hinges on its ability to scale production and secure commercial partnerships.
Evolva Holding SA competes in the biotechnology and synthetic biology space, focusing on nature-based ingredients. Its competitive advantage lies in its proprietary fermentation and bioconversion technologies, which enable cost-effective and sustainable production of high-value compounds. Unlike traditional chemical synthesis, Evolva's methods align with growing regulatory and consumer preferences for natural ingredients. However, the company faces intense competition from larger firms with greater R&D budgets and established distribution networks. Evolva's niche focus on flavors, fragrances, and health ingredients differentiates it, but scalability remains a challenge. The company's partnerships with industry players could enhance its market position, but it must navigate the capital-intensive nature of biotech commercialization. Competitors range from global flavor and fragrance giants to specialized biotech firms, requiring Evolva to continuously innovate and demonstrate cost competitiveness.